GFI Group Selects Aleri’s CEP and Live OLAP Technology for Real-Time Risk Monitoring
Aleri’s technology allows GFI to monitor market and credit risk in real-time
GFI Group Selects Aleri’s CEP and Live OLAP Technology for Real-Time Risk Monitoring
(TradeTech)-- Aleri Inc., a leading provider of enterprise-class complex event processing (CEP) technology and CEP-based solutions, today announced that GFI Group Inc. (www.GFIgroup.com ), a leading inter-dealer broker specializing in over-the-counter derivatives products and related securities, will deploy Aleri’s Real-Time Risk (RtRisk) Monitoring solution that combines CEP and Live OLAP technology to gain immediate insight into their pre- and post-execution risk.
“We looked at several other options and concluded that Aleri’s RtRisk Monitoring solution was the best fit,” said Brian Farrelly, Operations Strategic Projects Director, at GFI. “We believe we shall be able to easily and quickly integrate the Aleri solution into our existing enterprise architecture, allowing us to aggregate data from across all businesses and products providing an immediate comprehensive view of our overall market and credit risk.”
With Aleri’s RtRisk Monitoring solution, GFI will be able to consolidate and analyze positions both periodically and in real-time to help identify unacceptable levels of exposure along a number of configurable dimensions, including counterparty, trader, asset class, region and industry sector. The solution will give GFI the unique ability to determine the underlying cause of the exposure right down to individual trades.
“Credit and market exposures are often managed by a number of different systems making monitoring and maintaining critical market and credit risk data a challenge for some firms,” said Don DeLoach, CEO of Aleri. “We are happy that we are able to provide GFI with an easy solution that allows them to see all exposures and concentrations in one view, business section-wide or globally.”
The need to manage and have “Continuous Intelligence” about risks being taken is absolutely vital. In the current, highly volatile market, events can occur and evolve in a matter of minutes and it’s the first to respond to adverse events that are best placed to weather such events. Additionally, it is also essential to have a holistic view of all aspects of Counterparty, Market and Credit Risk. Aleri’s RtRisk Monitoring solution framework provides comprehensive tools to enable firms like GFI to map Counterparty Interrelationships to better understand their potential exposure to Systemic Risk. It employs the latest CEP and Live OLAP technology to enable clients to achieve a holistic view of their exposure in a flexible, timely and cost effective manner.
About Aleri
Aleri, a leading provider of enterprise-class complex event processing (CEP) technology and CEP-based solutions for financial services, provides a high performance platform to quickly build and deploy real-time data analysis applications, without compromising data management, scalability, performance, or security. Built for high throughput with minimal latency, Aleri’s event processing technology allows customers to analyze and respond instantly to high-volume, high-speed data to minimize risk and increase competitive advantage.
Aleri’s CEP powered solutions help translate real-time data into insight, enabling the financial industry to respond faster to changing conditions and to make better decisions through more timely information. The Aleri Liquidity Management System leverages the power of CEP to provide end-to-end real-time management of cash and liquid assets to reduce short term liquidity risk and ensure optimal funding. The Aleri Market Liquidity Analysis engine consolidates and analyzes multiple order book feeds from individual exchanges to provide a powerful tool for trading in fragmented markets.
Aleri is a global company headquartered in Chicago with offices in Mountain View, New York, New Jersey, London, and Paris. For more information, visit www.aleri.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
Cognito Europe
Adam Honeysett-Watts/Camilla Pepper, +44 (0)20 7438
1100
aleri@cognitomedia.com
or
Cognito
US
Deborah Eisenberg/Ishviene Arora, +1 646-395-6300
aleri@cognitomedia.com
or
Aleri
Kelly
Shumaker, +1 312-540-7347
kelly.shumaker@aleri.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom